NCT02246634 Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
| NCT ID | NCT02246634 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imperial College London |
| Condition | Colorectal Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 282 participants |
| Start Date | 2014-08 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 282 participants in total. It began in 2014-08 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years. Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.
Eligibility Criteria
Inclusion Criteria: 1. Have a high risk primary colorectal malignancy 2. Have a negative CT or includes no confirmatory evidence of liver metastases 3. Is able to undergo treatment if liver metastasis is found 4. Have provided written informed consent to participate in the study 5. Be aged 16 years or over Exclusion Criteria: 1. Have had a previous colorectal malignancy 2. Have metastatic disease 3. Have a synchronous second malignancy 4. Are contraindicated for MRI 5. Has a T3b or below low rectal tumour without EMVI or N1c
Contact & Investigator
Gina Brown
PRINCIPAL INVESTIGATOR
Imperial College London
Frequently Asked Questions
Who can join the NCT02246634 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Colorectal Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02246634 currently recruiting?
Yes, NCT02246634 is actively recruiting participants. Contact the research team at c.martin1@imperial.ac.uk for enrollment information.
Where is the NCT02246634 trial being conducted?
This trial is being conducted at Macclesfield, United Kingdom, Burton-on-Trent, United Kingdom, Chelmsford, United Kingdom, Bolton, United Kingdom and 9 additional locations.
Who is sponsoring the NCT02246634 clinical trial?
NCT02246634 is sponsored by Imperial College London. The principal investigator is Gina Brown at Imperial College London. The trial plans to enroll 282 participants.